Mar Llamas-Velasco
Overview
Explore the profile of Mar Llamas-Velasco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
2.
Jimenez-Sanchez A, Olivares-Guerrero M, Aparicio-Dominguez M, Berenguer-Ruiz S, Juarez-Salcedo L, Munoz-Hernandez P, et al.
Leuk Lymphoma
. 2024 Nov;
66(3):541-547.
PMID: 39540395
No abstract available.
3.
Lebwohl M, Bukhalo M, Gold L, Glick B, Llamas-Velasco M, Sanchez-Rivera S, et al.
J Am Acad Dermatol
. 2024 Aug;
91(6):1150-1157.
PMID: 39208985
Background: In plaque psoriasis, palmoplantar areas are more difficult to treat. Objective: Evaluate the safety and efficacy of risankizumab (RZB) versus placebo (PBO) for the treatment of palmoplantar psoriasis. Methods:...
4.
Chiricozzi A, Coscarella G, Puig L, Vender R, Yeung J, Carrascosa J, et al.
J Eur Acad Dermatol Venereol
. 2024 Jun;
38(11):2175-2185.
PMID: 38860729
Background: Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. Objectives: To evaluate the drug survival of interleukin (IL)-23 or the...
5.
Sahuquillo-Torralba A, Mansilla-Polo M, Pujol-Marco C, Llamas-Velasco M, Rull E, Ruiz Villaverde R, et al.
Int J Dermatol
. 2024 May;
63(12):1720-1727.
PMID: 38736107
Background: Certolizumab is an Fc-free PEGylated tumor necrosis factor-alpha (TNFα) inhibitor recently approved for the treatment of moderate-to-severe plaque psoriasis, although there is limited real-world evidence on the effectiveness and...
6.
Fernandez Figueras M, Alzoghby-Abi Chaker J, Fernandez-Parrado M, Garcia Herrera A, Garrido M, Idoate Gastearena M, et al.
Rev Esp Patol
. 2024 Apr;
57(2):97-110.
PMID: 38599743
This is the second article in a two-part series published in this journal, in which we examine the histopathological characteristics, as well as the differential diagnosis, of the main entities...
7.
Berna-Rico E, Abbad-Jaime de Aragon C, Ballester-Martinez A, Perez-Bootello J, Solis J, Fernandez-Friera L, et al.
J Invest Dermatol
. 2024 Mar;
144(9):2002-2012.e2.
PMID: 38460808
Systemic inflammation or insulin resistance drive atherosclerosis. However, they are difficult to capture for assessing cardiovascular risk in clinical settings. The monocyte-to-high-density lipoprotein ratio (MHR) is an accessible biomarker that...
8.
Fernandez-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396877
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA...
9.
Torres T, Chiricozzi A, Puig L, Le A, Marzano A, Dapavo P, et al.
Am J Clin Dermatol
. 2024 Jan;
25(2):333-342.
PMID: 38265746
Background: Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation,...
10.
Sanchez-Pellicer P, Eguren-Michelena C, Garcia-Gavin J, Llamas-Velasco M, Navarro-Moratalla L, Nunez-Delegido E, et al.
Front Microbiol
. 2024 Jan;
14:1323644.
PMID: 38260914
Rosacea is an inflammatory skin disease involving diverse symptoms with a variable clinical progress which can severely impact the patient's quality of life as well as their mental health. The...